China Tracker - Details for China Sky One Medical (CSKI)

 China Sky One Medical
Shares Outstanding (MRQ): 16.94 mill
New Shares / Dilution (TTM): -0.01 mill-0.09%
New Shares / Dilution (since Dec 31, 2008): 1.51 mill9.80% 
Cash (MRQ): 48.06 mill0.00%
Account Receivables (MRQ): 16.68 mill0.00%
Account Receivables (Q/Q): -3.40 mill  
Long-Term Debt (MRQ): NO DEBT
Revenue Growth (Q/Q): 5.82% 
Revenue Growth (Y/Y): -1.86%
Net Income Growth (Q/Q): 90.68% 
Net Income Growth (Y/Y): -38.06%
EPS Growth (Y/Y): -38.00%
Net Margin (Q/Q): 16.7% (9.3%)7.40% 
Net Margin (Y/Y): 16.7% (26.5%)-9.80% 
EPS | P/E (2 MRQ Projection): $0.850.00 
CFPS | P/CF (2 MRQ Projection): $1.900.00 
Price/Sales (2 MRQ Projection): 0.00
Price/Book (MRQ): 0.00 
Auditor: MSPC (Moore Stephens) 
 
 Forward Projections (Fiscal Year)
EPS | P/E (Estimates updated 2010-10-31): $1.600.00 
 Basic Facts and History (show more)
Reporting Type: U.S. Company (10-K Filings) 
Going Public: Reverse Merger on 2006-05-11 
Uplisting to Senior Exchange: on 2008-05-28 at $12.30 (-100.00% since Uplisting)

 Business Outlook

COVERAGE TERMINATED (Going Dark)
Recent Chain of Events:
2012-04-03 -- Last SEC Filing
2012-03-12 -- Auditor Resignation
2011-03-08 -- Delisting from NASDAQ
2011-02-16 -- Trading halted by NASDAQ
2011-12-16 -- CFO Resignation
2011-11-09 -- Last Quarterly/Annual Report: Q3/FY2011 ended September 30, 2011

(Source: Trading China, 2012-09-30)

The U.S. Securities and Exchange Commission charged China Sky One Medical and its chief executive with securities fraud and said the company recorded fake sales of a weight loss product. China Sky One inflated revenues in its financial statements by booking $19.8 million in phony export sales, the SEC said.

The company, based in China, said in 2007 securities filings it had entered into a distribution agreement with a Malaysian company that would generate the sales, but never entered into such an agreement, the SEC said on Tuesday.

(Source: Reuters, 2012-09-05)

China Sky One Medical has won the bidding process on 50-year land use rights covering approximately 85,000 m2 of land located in the High-Tech Development Zone of Song Bei District in Harbin, China. The Company acquired the Land Use Rights for total consideration of approximately $7.3 million, which was originally deposited by the Company's wholly owned subsidiary, Harbin Tian Di Ren Medical Science and Technology Company, to Harbin High-Tech Development Zone during the second quarter of 2010. The Company intends to build a research and development center, an injection manufacturing facility, a logistics center and an office building on the Land during the first phase of development, which the Company currently expects to complete in the mid of 2012.

(Source: PR Newswire, 2011-07-19)

    see all Business Outlook notes

 Investor Presentations
2010-05-08 (HTML)   VIEW
CSKI
Healthcare & Drugs
SCORE
-1
UNDER REVIEW
READ: Score Cards Explained
SAFETY/RISK SCORE
EXTREME RISK
DETAILS: Safety/Risk Model for CSKI
Current Price:  n/a
F10k Day (2006-09-15): -100.00%$7.00
2009 Close: -100.00%$22.75
2010 Close: -100.00%$6.97
2011 Close: -100.00%$0.99
High (2012-02-14): -100.00%$1.63
Low (2012-07-18): -100.00%$0.25
Exchange:
Market Capitalization: n/a
Total Shares: 16.94 mill
Float: n/a
Avg Volume: 101.50 k
Short Interest: 1.69 mill
Short Ratio: 17.38%16.6 d
Last Quarter: 2011-03-31
Revenue (MRQ): 28.37 mill
Net Income (MRQ): 4.75 mill
Op. Cash Flow (MRQ): 9.04 mill
all financial data provided without warranty